TY - CHAP
T1 - Routes of Administration for Carriers for Lymphatic Delivery
AU - Tagoe, Benjamin
AU - Gyamfi, David
AU - Ofori, Emmanuel Kwaku
AU - Quaye, Benedcita
AU - Amponsah, Seth Kwabena
N1 - Publisher Copyright:
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - The administration of drugs into the lymphatic system has garnered interest over the last few years. Indeed, the lymphatic system plays a significant role in the pathophysiology of diseases such as cancer, inflammation, and metabolic disorders. There is a possibility that the administration of drugs into lymph tissues could improve the treatment of these diseases. Studies have shown that there is a decrease in the first-pass metabolism when drugs go through the lymphatic system. This ultimately leads to an increase in the amount of drug in circulation. Different nanoformulations based on lipids, such as solid lipid nanoparticles and nanostructured lipid carriers, possess distinctive qualities that make them viable candidates for lymphatic administration. Furthermore, to assist in managing disease, it is possible to provide therapy by means of drug-encapsulated colloidal carriers, particularly liposomes and solid lipid nanoparticles. In drug administration, choosing the appropriate route and target area is of utmost importance. Routes that promotelym phatic access and retain drug molecules can lower systemic toxicities and boost bioavailability of poorly soluble and unstable drugs. Routes of administration for carriers into the lymphatic system are discussed in this chapter.
AB - The administration of drugs into the lymphatic system has garnered interest over the last few years. Indeed, the lymphatic system plays a significant role in the pathophysiology of diseases such as cancer, inflammation, and metabolic disorders. There is a possibility that the administration of drugs into lymph tissues could improve the treatment of these diseases. Studies have shown that there is a decrease in the first-pass metabolism when drugs go through the lymphatic system. This ultimately leads to an increase in the amount of drug in circulation. Different nanoformulations based on lipids, such as solid lipid nanoparticles and nanostructured lipid carriers, possess distinctive qualities that make them viable candidates for lymphatic administration. Furthermore, to assist in managing disease, it is possible to provide therapy by means of drug-encapsulated colloidal carriers, particularly liposomes and solid lipid nanoparticles. In drug administration, choosing the appropriate route and target area is of utmost importance. Routes that promotelym phatic access and retain drug molecules can lower systemic toxicities and boost bioavailability of poorly soluble and unstable drugs. Routes of administration for carriers into the lymphatic system are discussed in this chapter.
KW - Drug delivery
KW - Lymphatic system
KW - Route of administration
UR - https://www.scopus.com/pages/publications/105001892358
U2 - 10.1007/978-3-031-64828-1_15
DO - 10.1007/978-3-031-64828-1_15
M3 - Chapter
AN - SCOPUS:105001892358
SN - 9783031648274
SP - 295
EP - 310
BT - Advanced Targeting of the Lymphatic System
PB - Springer Nature
ER -